Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Integrilin

Function:
For the treatment of acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction), including patients who will receive medical therapy or are scheduled to undergo percutaneous coronary intervention (PCI).

Dosage:
The safety and efficacy of eptifibatide have been established in clinical studies with concomitant use of heparin and aspirin. For patients with acute coronary syndrome and normal renal function: The recommended adult dose of eptifibatide is a rapid intravenous bolus injection of 180 µg/kg as soon as possible after diagnosis, followed by a continuous intravenous infusion of 2.0 µg/kg/minute until discharge or initiation of treatment. For coronary artery bypass grafting (CABG) surgery, the total treatment time can be up to 72 hours. If the patient is preparing to undergo percutaneous coronary intervention (PCI) while taking eptifibatide, the intravenous infusion should continue until discharge or 18 to 24 hours after PCI (whichever is shorter), and the total treatment duration can reach 96 Hour. Patients with renal impairment who have a creatinine clearance <50 ml/minute but are not dependent on dialysis: For patients with acute coronary syndrome who have a creatinine clearance <50 ml/minute (calculated using the Cockroft-Gault formula), the recommended adult dose of eptifibatide is Rapid intravenous bolus injection of 180 µg/kg as soon as possible after diagnosis, followed immediately by continuous intravenous infusion of 1.0 µg/kg/minute. *Calculate creatinine clearance (Ccr) using the Cockroft-Gault formula based on the patient's actual weight: Patients undergoing coronary artery bypass grafting should stop intravenous infusion of eptifibatide before surgery. Patients requiring treatment with thrombolytic agents should discontinue eptifibatide. Recommended Aspirin and Heparin Dosing In clinical studies showing the effectiveness of eptifibatide, most patients were given concomitant aspirin and heparin. The recommended dosage is as follows: Aspirin: 75 to 300 mg, taken orally, once a day, at the beginning of treatment. Heparin: Target during drug treatment: APTT value 50 to 70 seconds. Target during PCI: ACT value 200~300 seconds. Heparin is not recommended after PCI. Instructions for use: As with other parenteral drugs, eptifibatide injection should be checked for particulate matter and color changes before administration. Epitibatide injection can be combined with alteplase, atropine, dobutamine, heparin, lidocaine, pethidine, metoprolol, midazolam, morphine, nitroglycerin or verapamil Administer via the same intravenous access, but not via the same intravenous access as furosemide. Eptifibatide injection can be administered through the same intravenous channel as 0.9% NaCl or 0.9% NaCl/5% glucose solution, and the infusion can contain up to 60mmol/L potassium chloride. No incompatibility between eptifibatide and intravenous delivery devices was observed. Epitibatide is drawn from a 10 ml bottle into a syringe for intravenous injection. Immediately after intravenous bolus administration of eptifibatide, continuous infusion is required. When using an infusion device for infusion and administration, pump 3 bottles of 10 ml eptifibatide injection into 50 ml of 0.9% NaCl or 0.9% NaCl/5% glucose injection, shake well, and use for intravenous infusion. The dosage of eptifibatide depends on the patient's weight. Drug contraindications: Do not use if allergic to this product and have renal impairment. Use with caution Related dosage forms: injection

Brand: injection Categories:

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.